U.S. Physical Therapy (USPH) Q4 2025 earnings review
Record Volume and Margin Expansion Overshadow GAAP Distortions
U.S. Physical Therapy closed out 2025 with strong operational execution. Revenue grew 12.3% YoY in Q4 to $202.7M, and Adjusted EBITDA expanded 13.5% to $24.8M. Management has successfully neutralized multi-year Medicare rate cuts, pushing the net rate per visit to $106.49 and driving average daily visits to an all-time Q4 high of 32.7. While GAAP EPS showed a sobering $0.44 loss per share, this was entirely driven by non-cash revaluations of non-controlling interests and earn-out liabilities. With a 1.75% Medicare rate hike and massive hospital alliance integrations slated for 2026, the company is guiding for accelerating underlying profitability.
🐂 Bull Case
After years of enduring cumulative statutory cuts, USPH will benefit from an estimated 1.75% Medicare rate increase beginning January 1, 2026. This instantly adds approximately $2.5M in high-margin incremental revenue.
Two newly announced 10-year strategic hospital alliances will transition 70 of USPH's existing clinics into hospital clinical services networks. Once fully ramped in late 2026, this is expected to add over $7.3M to USPH's share of EBITDA.
🐻 Bear Case
Virtually all Q4 Physical Therapy revenue growth came from acquired clinics. Revenue from 'Mature Clinics' (open prior to Jan 1, 2024) grew a mere 1.4% YoY. The company is relying heavily on M&A to mask flat same-store top-line performance.
CFO Carey Hendrickson is resigning in April 2026. Transitioning top financial leadership while in the middle of a multi-year enterprise financial and HR system implementation adds significant execution risk.
⚖️ Verdict: 🟢
Bullish. The core operational engine is highly efficient. They are stuffing record patient volumes through their clinics while successfully managing labor costs per visit. The shift from Medicare headwinds to tailwinds, coupled with the highly accretive hospital alliances, creates a clear path to the $102M-$106M EBITDA guidance.
Key Themes
Clinic Productivity Operating at Max Capacity
Stable and exceptional. Average daily patient visits per clinic hit 32.7 in Q4, tying the all-time record set in Q2 2025 and up from 31.6 a year ago. By increasing throughput without proportionally raising fixed costs, USPH drove PT gross profit margins up dramatically from 18.3% to 20.2% YoY.
Mature Clinic Revenue is Stagnant
Decelerating. Revenue from Mature Clinics was $133.5M in Q4, up just 1.4% YoY from $131.6M. By comparison, clinic additions contributed $35.7M (up from $17.1M). While M&A integration is successful, the core legacy footprint is showing virtually zero top-line elasticity despite higher net reimbursement rates.
Industrial Injury Prevention (IIP) Continues to Scale
Accelerating. The IIP segment posted another strong quarter, with revenue growing 8.7% YoY to $28.9M. Margins also expanded to 17.1% from 16.7%. The segment closed out the year generating $114.4M in total revenue (+18% YoY), proving that cross-selling initiatives and new industry verticals are paying off.
GAAP Earnings Noise Obscures Real Performance
Stable, but severely distorting. USPH reported a GAAP Net Loss of $0.44 per share in Q4. This was driven by a $10.8M reduction to earnings related to the surging value of redeemable non-controlling interests (partner equity) and a $5.2M loss on contingent earn-out considerations. Because USPH succeeds operationally, the value of partner buyouts rises, paradoxically crushing GAAP Net Income.
Elevated Corporate Overhead from ERP Implementation
Corporate office costs remain elevated, increasing to 8.9% of net revenue in Q4 from 8.6% a year ago. Management cites costs associated with acquisition integration and the rollout of a new financial and human resources system. These ERP-related implementation costs are explicitly guided to drag through the end of 2026.
Other KPIs
Accelerating. Up 30.7% from $7.8M ($0.51/share) in 24Q4. This is the cleanest metric to view USPH's bottom line, as it strips out the extreme volatility of put-right liabilities, clinic closure costs, and contingent earn-out fluctuations.
Stable. Down slightly from $86.06 a year ago. Despite wage inflation across the broader healthcare sector, USPH has successfully capped its per-visit expenses, allowing the $1.76 YoY increase in net rate to flow directly to the bottom line.
Accelerating. Up 11.2% YoY from 1,432,801. This sheer volume throughput is the mechanical engine behind the 25.3% explosion in Q4 physical therapy gross profit.
Guidance
Accelerating. At the $104.0M midpoint, this implies 9.5% YoY growth over 2025's $95.0M. Management notes this includes the 1.75% Medicare update and a phased ramp-up of the strategic hospital alliances beginning mid-year.
Key Questions
Hospital Alliance Integration Friction
The NYU Langone and secondary hospital alliances promise >$7.3M in annualized EBITDA for USPH's share once fully integrated. What specific upfront capital expenditures, branding, or operational friction should we expect in H1 2026 before the mid-year launch?
Mature Clinic Growth Constraints
Mature clinic revenue grew just 1.4% YoY in Q4 despite an overall net rate increase. Are your established markets reaching absolute capacity ceilings for daily visits, or is there an unfavorable payer-mix shift happening in legacy clinics?
CFO Transition Impact
With Carey Hendrickson departing right as the company enters a massive ERP implementation phase and scales major hospital JV networks, will M&A activity be temporarily slowed down to ensure financial reporting stability?
Share Repurchase Philosophy
You repurchased $5.6M of stock in Q4 under the $25M authorization. Given the highly accretive nature of current M&A and the impending hospital alliances, why deploy capital to buybacks now rather than retaining it for immediate strategic deployment?